Cargando…
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/06/2018) (and, for immunotherapy, ASCO and ES...
Autores principales: | Jardim, Denis L., De Melo Gagliato, Débora, Nikanjam, Mina, Barkauskas, Donald A., Kurzrock, Razelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959453/ https://www.ncbi.nlm.nih.gov/pubmed/32002305 http://dx.doi.org/10.1080/2162402X.2019.1710052 |
Ejemplares similares
-
Lessons From the Development of the Immune Checkpoint Inhibitors in
Oncology
por: Jardim, Denis L., et al.
Publicado: (2018) -
Tumor mutational burden is not predictive of cytotoxic chemotherapy response
por: Nikanjam, Mina, et al.
Publicado: (2020) -
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019) -
Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016) -
Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)